India is about to see a major shift in access to weight-loss medications as the patent for semaglutide the key ingredient behind blockbuster drugs like Wegovy and Ozempic expires. This will allow local pharmaceutical companies to produce cheaper generic versions, likely triggering intense competition and cutting prices by more than half.
India’s strong generics industry is expected to move quickly, with dozens of versions of semaglutide entering the market within months. Major companies are already preparing to launch their own products, and monthly treatment costs could drop from roughly 8,800–16,000 rupees to about 3,000–5,000 rupees. This price reduction could significantly expand access, especially in a country with over 77 million people living with type 2 diabetes and a large population struggling with obesity.
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which help control appetite and blood sugar by increasing insulin release and slowing digestion. Originally developed for diabetes, these drugs are now widely used for weight loss due to their effectiveness.
Demand for such treatments has already been rising in India, especially after the introduction of Rybelsus, the first oral version of semaglutide. The broader anti-obesity drug market has grown rapidly and is expected to expand even further as prices fall.
Beyond endocrinology, these drugs are increasingly used across medical fields for example, to help patients lose weight before surgeries or manage conditions like sleep apnea. Doctors believe cheaper access could benefit millions, but they also stress caution.
There are concerns about side effects, including nausea, digestive issues, and more serious complications in rare cases. Rapid weight loss without proper nutrition or exercise can also lead to muscle loss. Additionally, patients often regain weight after stopping the medication, as appetite tends to return strongly.
Experts also warn about potential misuse, especially as prices drop. Some patients may seek quick results influenced by social media, while unqualified practitioners or online platforms might prescribe the drugs inappropriately. This raises the risk of overuse or unsafe dosing.
India’s role as a global supplier of affordable generics means the impact could extend far beyond its borders, potentially improving access to weight-loss treatments worldwide. However, maintaining strict quality standards and proper regulation will be critical to ensuring safety and preserving trust in these medicines.
In short, while cheaper semaglutide could transform obesity treatment and diabetes care, its success will depend on balancing affordability with responsible use and strong oversight.
